Related Experiment Video
Updated: May 17, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Model-Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma
Xiaozhi Liao1, Tommy Li2, Steven Xu2
1University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Clinical Pharmacology and Therapeutics
|May 15, 2026
Summary
Evaluating dosing strategies for epcoritamab in large B-cell lymphoma (LBCL) shows continuous treatment after complete response (CR) may improve long-term outcomes. This modeling approach aids in optimizing therapy for relapsed or refractory LBCL patients.
Area of Science:
- Pharmacometrics and Drug Development
- Oncology and Hematology
- Clinical Trial Simulation
Background:
- Dose selection for novel therapies like bispecific antibodies is challenging, especially in relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
- Direct comparison of alternative dosing regimens in patients is often ethically constrained.
- Epcoritamab is a CD3xCD20 bispecific antibody used in R/R LBCL.
Purpose of the Study:
- To develop and apply a joint model to evaluate alternative post-complete response (CR) dosing strategies for epcoritamab monotherapy in R/R LBCL.
- To simulate long-term efficacy outcomes for continuous, fixed-duration, and stop-at-CR dosing strategies.
- To identify potential predictors for patients benefiting from continuous epcoritamab treatment.
Main Methods:
- Developed a joint pharmacokinetic/pharmacodynamic model integrating Deauville scores using clinical data from 165 R/R LBCL patients.
- Simulated three post-CR dosing strategies (continuous, fixed-duration, stop-at-CR) in 1,000 virtual patients.
- Defined responder subgroups by CR durability and explored predictors of continuous treatment need.
Main Results:
- Simulations suggested continuous epcoritamab treatment post-CR is associated with higher long-term CR rates: 46.4% (continuous) vs. 37.2% (fixed-duration) vs. 27.0% (stop-at-CR) at 2 years.
- Exploratory analyses indicated early tumor reduction and circulating tumor DNA levels may identify patients benefiting from continuous therapy.
- The modeling framework quantitatively assessed epcoritamab dosing strategies in R/R LBCL.
Conclusions:
- Model-based simulations support the potential value of continuous epcoritamab therapy for maintaining long-term CR in R/R LBCL.
- The developed joint model provides a quantitative approach for evaluating alternative dosing strategies.
- Further validation incorporating safety outcomes is necessary for comprehensive clinical decision-making.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...